A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

  • Tran, Huyen (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date20/01/23 → 19/01/25

Keywords

  • Clinical trial
  • haematological malignancy
  • VTE

Clinical Trial Phase

  • Phase III (a & b)